-91%

est. 2Y upside i

HealthcareSeed

We provide a curated, evidence- based answer to any clinical question.

Rank

#2636

Sector

Healthcare Technology

Est. Liquidity

~4Y

Data Quality

Data: Medium

InpharmD is an early-stage healthcare AI company with a promising hybrid model and $16M in revenue, but faces significant incumbent threats from established players like Wolters Kluwer (UpToDate) and EHR giants.

Last updated: March 10, 2026

Bull (15%)+200%

InpharmD rapidly expands its customer base by demonstrating superior ROI and fending off incumbent threats through its unique AI + human pharmacist hybrid model. This drives revenue to over $40M ARR within two years, justifying a Series B valuation of $120M.

Base (45%)+75%

InpharmD continues its steady growth, securing a successful Series A round. It reaches approximately $27M ARR within two years, maintaining its market position and achieving a valuation of $70M.

Bear (40%)-75%

Dominant incumbents like Wolters Kluwer (UpToDate) or EHR giants like Epic launch more robust, competing AI-driven clinical decision support features, significantly slowing InpharmD's customer acquisition and growth. This leads to a challenging fundraising environment and a down round, resulting in a valuation of $10M and substantial loss for common shareholders.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Investors hold $7M in liquidation preferences, representing 17.5% of the estimated $40M current valuation. In an exit at or below $7M, common stock holders would receive nothing.

Dilution Risk

high

As a seed-stage company, significant dilution is expected from future Series A and B funding rounds required to scale the business.

Secondary Liquidity

none

There is no active secondary market for InpharmD's shares at this early stage of company development.

View all 4 open roles at InpharmD →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on InpharmD's data — designed to show you've done your homework.

  • 1

    “Given that dominant incumbents like Wolters Kluwer (UpToDate) and EHR giants like Epic are actively integrating AI into their clinical decision support offerings, how does InpharmD plan to maintain its competitive moat and differentiate its hybrid AI-pharmacist model over the next 2-3 years?”

  • 2

    “With $16M in revenue and a recent $6M seed round, what are the key milestones InpharmD aims to achieve in terms of customer acquisition and revenue growth to secure a successful Series A or B funding round, and what is the expected burn rate over the next 12-18 months?”

  • 3

    “Considering the seed-stage funding and the potential for future dilution, how is the company thinking about a liquidity event timeline for employees, and are there any plans for secondary liquidity options for common stock holders within a 2-5 year horizon?”

Community

Valuation Sentiment

Our model estimates -91% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.